Search | OpenScholar

Search results

193 results found

Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Mov Disord Clin Pract 2018;5:627-634.

Publication: Journal Article

Hauser, RA, I Biaggioni, LA Hewitt, and S Vernino. 2018. “Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients With Parkinson Disease. Mov Disord Clin Pract 2018;5:627-634.”. Mov Disord Clin Pract.

NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.

Publication: Journal Article

Hauser, RA, R Li, A Perez, X Ren, D Weintraub, J Elm, JL Goudreau, et al. 2017. “NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure Is Associated With Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.”. J Parkinsons Dis.

Design of a cluster-randomized minority recruitment trial: RECRUIT. Clin Trials 2017;14:286-298.

Publication: Journal Article

Tilley, BC, AG Mainous, DW Smith, MD McKee, RP Amorrortu, J Alvidrez, V Diaz, et al. 2017. “Design of a Cluster-Randomized Minority Recruitment Trial: RECRUIT. Clin Trials 2017;14:286-298.”. Clin Trials.

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord 2017;32:1335-1336.

Publication: Journal Article

Goetz, CG, GT Stebbins, KA Chung, AP Nicholas, RA Hauser, D Merkitch, and MA Stacy. 2017. “Topiramate As an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study. Mov Disord 2017;32:1335-1336.”. Mov Disord.

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism Relat Disord 2020;81:144-150.

Publication: Journal Article

Farbman, ES, CH Waters, PA LeWitt, M Rudinska, M Klingler, A Lee, J Qian, C Oh, and RA Hauser. 2020. “A 12-Month, Dose-Level Blinded Safety and Efficacy Study of Levodopa Inhalation Powder (CVT-301, Inbrija) in Patients With Parkinson’s Disease. Parkinsonism Relat Disord 2020;81:144-150.”. Parkinsonism Relat Disord.

Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2020;20:1-10.

Publication: Journal Article

Hauser, RA, JM Meyer, SA Factor, CL Comella, CM Tanner, RM Xavier, SN Caroff, and L Lundt. 2020. “Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice. CNS Spectr 2020;20:1-10.”. CNS Spectr.

Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int J Neurosci 2016;126:20-24

Publication: Journal Article

Kumar, R, RA Hauser, J Mostillo, N Dronamraju, A Graf, M Merschemke, and C Kenney. 2016. “Mavoglurant (AFQ056) in Combination With Increased Levodopa Dosages in Parkinson’s Disease Patients. Int J Neurosci 2016;126:20-24”. Int J Neurosci.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72:88-95.

Publication: Journal Article

Smith, KM, E Eyal, D Weintraub, and Adagio Investigators. 2015. “Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability. JAMA Neurol 2015;72:88-95.”. JAMA Neurol.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.

Publication: Journal Article

Bega, D, S Kim, Y Zhang, J Elm, J Schneider, R Hauser, A Fraser, and T Simuni. 2015. “Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.”. J Parkinsons Dis.

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:268-75.

Publication: Journal Article

Low, PA, D Robertson, S Gilman, H Kaufmann, W Singer, I Biaggioni, R Freeman, et al. 2014. “Efficacy and Safety of Rifampicin for Multiple System Atrophy: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol 2014;13:268-75.”. Lancet Neurol.